Skip to content

SCOPUS BIOPHARMA INC.: 10-Q/A filed 2021-02-26

What SCOPUS BIOPHARMA INC. reported in its quarterly report amendment filed 2021-02-26 (fiscal Q3 2020): 28 published measures, 82 facts as tagged in accession 0001104659-21-029327.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2021-02-26
Fiscal period
fiscal Q3 2020
Accession
0001104659-21-029327 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SCOPUS BIOPHARMA INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-301,239,792USD
At 2019-12-31771,682USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-2,549,007USD
At 2020-06-30-1,505,035USD
At 2019-12-31-82,859USD
At 2019-09-30687,650USD
At 2019-06-301,099,102USD
At 2018-12-31-5,326USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-30420,557USD
At 2019-12-3136,747USD
At 2019-09-30670,407USD
At 2018-12-311,660USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,159,986USD92
2020-01-01 to 2020-09-30-9,811,383USD274
2019-07-01 to 2019-09-30-797,220USD92
2019-01-01 to 2019-09-30-1,726,062USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-1,605,996USD274
2019-01-01 to 2019-09-30-1,514,683USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-303,562USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,991,630USD274
2019-01-01 to 2019-09-302,186,694USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-13,450,830USD
At 2019-12-31-3,639,447USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-302,597USD
At 2019-12-313,659USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-30180,765USD274
2019-01-01 to 2019-09-30153,378USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-875,466USD92
2020-01-01 to 2020-09-30-9,441,718USD274
2019-07-01 to 2019-09-30-797,220USD92
2019-01-01 to 2019-09-30-1,726,062USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-301,237,195USD
At 2019-12-31768,023USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-07-01 to 2020-09-30284,520USD92
2020-01-01 to 2020-09-30369,665USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-303,788,799USD
At 2019-12-31854,541USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-30875,466USD92
2020-01-01 to 2020-09-309,441,718USD274
2019-07-01 to 2019-09-30797,220USD92
2019-01-01 to 2019-09-301,726,062USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-3069,421USD92
2020-01-01 to 2020-09-307,354,295USD274
2019-07-01 to 2019-09-3082,123USD92
2019-01-01 to 2019-09-30279,543USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3014,002,597shares
At 2019-12-3112,509,024shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3012,423,747USD
At 2019-12-313,577,533USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-09-30-35,927USD
At 2019-12-31-33,454USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-3066,507USD
At 2019-12-31104,260USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,159,986USD92
2020-01-01 to 2020-09-30-9,811,383USD274
2019-07-01 to 2019-09-30-797,220USD92
2019-01-01 to 2019-09-30-1,726,062USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-01-01 to 2020-09-309,811,383USD274
2019-01-01 to 2019-09-301,726,062USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,163,259USD92
2020-01-01 to 2020-09-30-9,813,856USD274
2019-07-01 to 2019-09-30-815,107USD92
2019-01-01 to 2019-09-30-1,744,626USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30806,045USD92
2020-01-01 to 2020-09-302,087,423USD274
2019-07-01 to 2019-09-30715,097USD92
2019-01-01 to 2019-09-301,446,519USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,073USD274
2019-01-01 to 2019-09-3084USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-09-30470USD274
2019-01-01 to 2019-09-300USD273

Inspect the source

Entity
SCOPUS BIOPHARMA INC. / CIK 0001772028
Captured
SEC response SHA-256
36a040addce65ff882f3e4144e7b7b41b7b674383b2d5847168ccc8a1fc1b82f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001772028.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))